CYTK - Cytokinetics, Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.96
+0.49 (+5.79%)
At close: 4:00PM EDT

8.96 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close8.47
Open8.47
Bid8.01 x 2200
Ask9.44 x 1800
Day's Range8.34 - 9.20
52 Week Range5.75 - 10.44
Volume831,845
Avg. Volume561,343
Market Cap496.143M
Beta (3Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)-1.95
Earnings DateApr 24, 2019 - Apr 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.50
Trade prices are not sourced from all markets
  • Will Cytokinetics (CYTK) Report Negative Q1 Earnings? What You Should Know
    Zacks5 days ago

    Will Cytokinetics (CYTK) Report Negative Q1 Earnings? What You Should Know

    Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire22 days ago

    Cytokinetics to Present at April Investor Conferences

    The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

  • GlobeNewswire22 days ago

    New Research Coverage Highlights International Paper, Square, Sealed Air, Calix, e.l.f. Beauty, and Cytokinetics — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
    Zacks27 days ago

    Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

    Key highlights of the past week are multiple study failures and other pipeline updates.

  • Benzingalast month

    The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 20) AstraZeneca plc (NYSE: AZN ) BioDelivery Sciences ...

  • Here's Why Cytokinetics Stock Jumped Today
    Motley Foollast month

    Here's Why Cytokinetics Stock Jumped Today

    The clinical-stage biotech's long-running partnership with Amgen took another big step forward.

  • GlobeNewswirelast month

    Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

    Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis, which included consideration of pre-specified criteria for futility. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial of omecamtiv mecarbil continue without changes to its conduct. The futility analysis was triggered once a pre-specified number of cardiovascular deaths had occurred in GALACTIC-HF as stipulated by the trial’s protocol.

  • PR Newswirelast month

    Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

    THOUSAND OAKS, Calif., and SOUTH SAN FRANCISCO, Calif., and SURESNES, France, March 20, 2019 /PRNewswire/ -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis, which included consideration of pre-specified criteria for futility. The futility analysis was triggered once a pre-specified number of cardiovascular deaths had occurred in GALACTIC-HF as stipulated by the trial's protocol.

  • GlobeNewswirelast month

    Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19

    Cytokinetics, Incorporated (CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, were presented by John Teerlink, M.D., Professor of Clinical Medicine, University of California San Francisco and Director of Heart Failure, San Francisco Veterans Affairs Medical Center, in a Moderated Poster Session at the American College of Cardiology’s 68th Annual Scientific Session (ACC.19) in New Orleans.

  • GlobeNewswirelast month

    Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19

    SOUTH SAN FRANCISCO, Calif., March 11, 2019 -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CYTK earnings conference call or presentation 21-Feb-19 9:30pm GMT

    Q4 2018 Cytokinetics Inc Earnings Call

  • GlobeNewswire2 months ago

    Cytokinetics Announces Presentation of Results From FORTITUDE-ALS at the American Academy of Neurology 71st Annual Meeting

    Cytokinetics, Incorporated (CYTK) today announced that results from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial of reldesemtiv in patients with amyotrophic lateral sclerosis (ALS), will be presented in a platform presentation at the American Academy of Neurology 71st Annual Meeting in Philadelphia on Sunday, May 5, 2019. FORTITUDE-ALS is designed to assess the change from baseline in the percent predicted slow vital capacity (SVC) and other measures of skeletal muscle function after 12 weeks of treatment with reldesemtiv (formerly CK-2127107). In collaboration with Astellas Pharma Inc. (Astellas), Cytokinetics is developing reldesemtiv, a next-generation fast skeletal muscle troponin activator (FSTA), as a potential treatment for people living with debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.

  • Some Cytokinetics Shareholders Are Down 43%
    Simply Wall St.2 months ago

    Some Cytokinetics Shareholders Are Down 43%

    The main aim of stock picking is to find the market-beating stocks. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn't blame longRead More...

  • GuruFocus.com2 months ago

    Cytokinetics Inc (CYTK) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Cytokinetics Inc is a biopharmaceutical company. Warning! GuruFocus has detected 3 Warning Signs with CYTK. For the last quarter Cytokinetics Inc reported a revenue of $9.38 million, compared with the revenue of $-0.02 million during the same period a year ago.

  • GlobeNewswire2 months ago

    Cytokinetics Joins Global Initiative To Recognize International Rare Disease Day

    Cytokinetics, Incorporated (CYTK) today announced that it is standing with the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disease Day®, an international campaign elevating the public understanding of rare diseases. This year’s theme for Rare Disease Day, “Bridging health and social care,” calls attention to the coordination between medical, social, and support services, and underscores the challenges people with rare diseases and their families face while balancing care and the demands of everyday life. “It’s our honor to once again join EURORDIS and NORD to bring awareness to Rare Disease Day.

  • Amgen Starts Phase III Enrollment for Heart Failure Drug
    Zacks2 months ago

    Amgen Starts Phase III Enrollment for Heart Failure Drug

    Amgen (AMGN) and partners started enrollment for the second phase III study of omecamtiv mecarbil, which is being developed for the potential treatment of heart failure with reduced ejection fraction.

  • Cytokinetics Inc (CYTK) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Cytokinetics Inc (CYTK) Q4 2018 Earnings Conference Call Transcript

    CYTK earnings call for the period ending December 31 2018.

  • Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates

    Cytokinetics (CYTK) delivered earnings and revenue surprises of 12.73% and 171.40%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Cytokinetics: 4Q Earnings Snapshot

    The South San Francisco, California-based company said it had a loss of 48 cents per share. The biopharmaceutical company posted revenue of $9.4 million in the period. For the year, the company reported ...

  • GlobeNewswire2 months ago

    Cytokinetics Reports Fourth Quarter 2018 Financial Results

    Company Provides 2019 Financial Guidance and Expected Milestones Reduced Operating Expenses vs. 2018; Over Two Years of Cash Based on Current Burn Rate Interim Analysis for.

  • GlobeNewswire2 months ago

    Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure

    THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). METEORIC-HF is designed to evaluate the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) in patients with HFrEF.

  • PR Newswire2 months ago

    Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

    THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 21, 2019 /PRNewswire/ -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). METEORIC-HF is designed to evaluate the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) in patients with HFrEF.

  • GlobeNewswire2 months ago

    Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator

    Cytokinetics, Incorporated (CYTK) today announced that the first subject has been dosed in a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 594 in healthy subjects. AMG 594 is a cardiac troponin activator, discovered under a joint research program conducted between Amgen and Cytokinetics. The study is being conducted by Amgen in collaboration with Cytokinetics.

  • The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
    Zacks2 months ago

    The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

    The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

  • Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know
    Zacks2 months ago

    Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know

    Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.